The niche segment of aryl-substituted cyclopropanecarboxylic acids has gained increasing attention as pharmaceutical companies seek novel scaffolds with improved metabolic stability and target selectivity. Among these compounds, 1 4 chlorophenyl cyclopropanecarboxylic acid stands out due to its favorable lipophilicity and ability to act as a constrained phenyl bioisostere in drug design. This...